Insulin-Like Growth Factor Binding Protein 1 as a Novel Specific Marker of Hepatic Insulin Sensitivity

Anna Kotronen, Moira Lewitt, Kerstin Hall, Kerstin Brismar, Hannele Yki-Jarvinen

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background and Aims: The liver is the main source and insulin the main regulator of IGF binding protein 1 (IGFBP-1) in humans. Here we examined how serum IGFBP-1 concentrations are related to directly measured hepatic insulin sensitivity and liver fat content in humans. Methods: We measured fasting serum (fS) IGFBP-1 concentrations and liver fat content by proton magnetic resonance spectroscopy in 113 nondiabetic subjects. In addition, hepatic insulin sensitivity was measured using the euglycemic hyperinsulinemic clamp (insulin 0.3 mU/kg.min) technique in combination with the infusion of [3-(3)H] glucose in 78 subjects. Results: fS-IGFBP-1 concentrations were inversely related to liver fat content (r = -0.38, P < 0.0001). Of circulating parameters, fS-IGFBP-1 was better correlated to hepatic insulin sensitivity (r = 0.48, P < 0.0001) than fS-insulin (r = -0.42, P = 0.0001), fS-C-peptide (r = -0.41, P = 0.0002), fS-triglyceride (r = -0.33, P = 0.003), or fS-high-density lipoprotein cholesterol (r = 0.30, P = 0.007). In multiple linear regression analyses, body mass index (P < 0.0001) and fS-IGFBP-1 (P = 0.008), but neither age nor gender, were independently associated with hepatic insulin sensitivity (P < 0.0001 for ANOVA). Neither fS-insulin nor fS-C-peptide were independent determinants of hepatic insulin sensitivity after adjusting for age, gender, and body mass index. Conclusions: fS-IGFBP-1 is inversely correlated with liver fat and is an obesity-independent and liver-specific circulating marker of hepatic insulin sensitivity.
Original languageEnglish
Pages (from-to)4867-4872
JournalThe Journal of Clinical Endocrinology & Metabolism
Volume93
Issue number12
DOIs
Publication statusPublished - Dec 2008

Keywords

  • MAGNETIC-RESONANCE-SPECTROSCOPY
  • DOSE-RESPONSE CHARACTERISTICS
  • METABOLIC SYNDROME
  • LIVER FAT
  • IGF-I
  • GLUCOSE
  • RESISTANCE
  • CIRRHOSIS
  • DISEASE
  • IGFBP-1

Cite this

Kotronen, Anna ; Lewitt, Moira ; Hall, Kerstin ; Brismar, Kerstin ; Yki-Jarvinen, Hannele. / Insulin-Like Growth Factor Binding Protein 1 as a Novel Specific Marker of Hepatic Insulin Sensitivity. In: The Journal of Clinical Endocrinology & Metabolism. 2008 ; Vol. 93, No. 12. pp. 4867-4872.
@article{eb765572f75f4fa790a42653f7337cd2,
title = "Insulin-Like Growth Factor Binding Protein 1 as a Novel Specific Marker of Hepatic Insulin Sensitivity",
abstract = "Background and Aims: The liver is the main source and insulin the main regulator of IGF binding protein 1 (IGFBP-1) in humans. Here we examined how serum IGFBP-1 concentrations are related to directly measured hepatic insulin sensitivity and liver fat content in humans. Methods: We measured fasting serum (fS) IGFBP-1 concentrations and liver fat content by proton magnetic resonance spectroscopy in 113 nondiabetic subjects. In addition, hepatic insulin sensitivity was measured using the euglycemic hyperinsulinemic clamp (insulin 0.3 mU/kg.min) technique in combination with the infusion of [3-(3)H] glucose in 78 subjects. Results: fS-IGFBP-1 concentrations were inversely related to liver fat content (r = -0.38, P < 0.0001). Of circulating parameters, fS-IGFBP-1 was better correlated to hepatic insulin sensitivity (r = 0.48, P < 0.0001) than fS-insulin (r = -0.42, P = 0.0001), fS-C-peptide (r = -0.41, P = 0.0002), fS-triglyceride (r = -0.33, P = 0.003), or fS-high-density lipoprotein cholesterol (r = 0.30, P = 0.007). In multiple linear regression analyses, body mass index (P < 0.0001) and fS-IGFBP-1 (P = 0.008), but neither age nor gender, were independently associated with hepatic insulin sensitivity (P < 0.0001 for ANOVA). Neither fS-insulin nor fS-C-peptide were independent determinants of hepatic insulin sensitivity after adjusting for age, gender, and body mass index. Conclusions: fS-IGFBP-1 is inversely correlated with liver fat and is an obesity-independent and liver-specific circulating marker of hepatic insulin sensitivity.",
keywords = "MAGNETIC-RESONANCE-SPECTROSCOPY, DOSE-RESPONSE CHARACTERISTICS, METABOLIC SYNDROME, LIVER FAT, IGF-I, GLUCOSE, RESISTANCE, CIRRHOSIS, DISEASE, IGFBP-1",
author = "Anna Kotronen and Moira Lewitt and Kerstin Hall and Kerstin Brismar and Hannele Yki-Jarvinen",
year = "2008",
month = "12",
doi = "10.1210/jc.2008-1245",
language = "English",
volume = "93",
pages = "4867--4872",
journal = "The Journal of Clinical Endocrinology & Metabolism",
issn = "0021-972X",
publisher = "Endocrine Society",
number = "12",

}

Insulin-Like Growth Factor Binding Protein 1 as a Novel Specific Marker of Hepatic Insulin Sensitivity. / Kotronen, Anna; Lewitt, Moira; Hall, Kerstin; Brismar, Kerstin; Yki-Jarvinen, Hannele.

In: The Journal of Clinical Endocrinology & Metabolism, Vol. 93, No. 12, 12.2008, p. 4867-4872.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Insulin-Like Growth Factor Binding Protein 1 as a Novel Specific Marker of Hepatic Insulin Sensitivity

AU - Kotronen, Anna

AU - Lewitt, Moira

AU - Hall, Kerstin

AU - Brismar, Kerstin

AU - Yki-Jarvinen, Hannele

PY - 2008/12

Y1 - 2008/12

N2 - Background and Aims: The liver is the main source and insulin the main regulator of IGF binding protein 1 (IGFBP-1) in humans. Here we examined how serum IGFBP-1 concentrations are related to directly measured hepatic insulin sensitivity and liver fat content in humans. Methods: We measured fasting serum (fS) IGFBP-1 concentrations and liver fat content by proton magnetic resonance spectroscopy in 113 nondiabetic subjects. In addition, hepatic insulin sensitivity was measured using the euglycemic hyperinsulinemic clamp (insulin 0.3 mU/kg.min) technique in combination with the infusion of [3-(3)H] glucose in 78 subjects. Results: fS-IGFBP-1 concentrations were inversely related to liver fat content (r = -0.38, P < 0.0001). Of circulating parameters, fS-IGFBP-1 was better correlated to hepatic insulin sensitivity (r = 0.48, P < 0.0001) than fS-insulin (r = -0.42, P = 0.0001), fS-C-peptide (r = -0.41, P = 0.0002), fS-triglyceride (r = -0.33, P = 0.003), or fS-high-density lipoprotein cholesterol (r = 0.30, P = 0.007). In multiple linear regression analyses, body mass index (P < 0.0001) and fS-IGFBP-1 (P = 0.008), but neither age nor gender, were independently associated with hepatic insulin sensitivity (P < 0.0001 for ANOVA). Neither fS-insulin nor fS-C-peptide were independent determinants of hepatic insulin sensitivity after adjusting for age, gender, and body mass index. Conclusions: fS-IGFBP-1 is inversely correlated with liver fat and is an obesity-independent and liver-specific circulating marker of hepatic insulin sensitivity.

AB - Background and Aims: The liver is the main source and insulin the main regulator of IGF binding protein 1 (IGFBP-1) in humans. Here we examined how serum IGFBP-1 concentrations are related to directly measured hepatic insulin sensitivity and liver fat content in humans. Methods: We measured fasting serum (fS) IGFBP-1 concentrations and liver fat content by proton magnetic resonance spectroscopy in 113 nondiabetic subjects. In addition, hepatic insulin sensitivity was measured using the euglycemic hyperinsulinemic clamp (insulin 0.3 mU/kg.min) technique in combination with the infusion of [3-(3)H] glucose in 78 subjects. Results: fS-IGFBP-1 concentrations were inversely related to liver fat content (r = -0.38, P < 0.0001). Of circulating parameters, fS-IGFBP-1 was better correlated to hepatic insulin sensitivity (r = 0.48, P < 0.0001) than fS-insulin (r = -0.42, P = 0.0001), fS-C-peptide (r = -0.41, P = 0.0002), fS-triglyceride (r = -0.33, P = 0.003), or fS-high-density lipoprotein cholesterol (r = 0.30, P = 0.007). In multiple linear regression analyses, body mass index (P < 0.0001) and fS-IGFBP-1 (P = 0.008), but neither age nor gender, were independently associated with hepatic insulin sensitivity (P < 0.0001 for ANOVA). Neither fS-insulin nor fS-C-peptide were independent determinants of hepatic insulin sensitivity after adjusting for age, gender, and body mass index. Conclusions: fS-IGFBP-1 is inversely correlated with liver fat and is an obesity-independent and liver-specific circulating marker of hepatic insulin sensitivity.

KW - MAGNETIC-RESONANCE-SPECTROSCOPY

KW - DOSE-RESPONSE CHARACTERISTICS

KW - METABOLIC SYNDROME

KW - LIVER FAT

KW - IGF-I

KW - GLUCOSE

KW - RESISTANCE

KW - CIRRHOSIS

KW - DISEASE

KW - IGFBP-1

U2 - 10.1210/jc.2008-1245

DO - 10.1210/jc.2008-1245

M3 - Article

VL - 93

SP - 4867

EP - 4872

JO - The Journal of Clinical Endocrinology & Metabolism

JF - The Journal of Clinical Endocrinology & Metabolism

SN - 0021-972X

IS - 12

ER -